

**UTILITY
PATENT APPLICATION
TRANSMITTAL**
(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 202930US0CIP
First Inventor or Application Identifier Jacques THEZE
Title PEPTIDES OF IL-2 AND DERIVATIVES THEREOF AND THEIR USE AS THERAPEUTIC AGENTS

JCS85

U.S.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. Fee Transmittal Form (e.g. PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. Specification Total Sheets **46**

3. Drawing(s) (35 U.S.C. 113) Total Sheets **27**

4. Oath or Declaration Total Pages

a. Newly executed (original or copy)
b. Copy from a prior application (37 C.F.R. §1.63(d))
(for continuation / divisional w/ box 17 completed)
i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in
the prior application, see 37 C.F.R. §1.63(d)(2) and
1.33(b).

5. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission
(If applicable, all necessary)

a. Computer Readable Form (CRF)
b. Specification or Sequence Listing on:
i. CD-ROM or CD-R (2 copies); or
ii. Paper
c. Statement verifying identity of above copies

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:

Continuation Divisional Continuation-in-part (CIP) of prior application no.: 09/660,465

Prior application information: Examiner:

Group Art Unit:

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. Amend the specification by inserting before the first line the sentence:

This application is a Continuation Division Continuation-in-part (CIP)
of application Serial No. 09/660,465 Filed on September 12, 2000, pending, which is a Continuation of Serial
Number 09/116,594, filed July 16, 1998, now U.S. Patent No.
6,168,785

Which was published in English
 Which was not published in English

This application claims priority of provisional application Serial No. Filed

19. CORRESPONDENCE ADDRESS



22850

(703) 413-3000

FACSIMILE: (703) 413-2220

Name:	Norman F. Oblon	Registration No.:	24,618
Signature:		Date:	02/06/01
Name:	Daniel J. Pereira, Ph.D.	Registration No.:	45,518

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) Jacques THEZE et al

SERIAL NO: New Application

FILING DATE: Herewith

FOR: PEPTIDES OF IL-2 AND DERIVATIVES THEREOF AND THEIR USE AS THERAPEUTIC AGENTS

FEE TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	34 - 20 =	14	× \$18 =	\$252.00
INDEPENDENT CLAIMS	5 - 3 =	2	× \$80 =	\$160.00
■ MULTIPLE DEPENDENT CLAIMS (If applicable)			+ \$270 =	\$270.00
■ LATE FILING OF DECLARATION			+ \$130 =	\$130.00
			BASIC FEE	\$710.00
			TOTAL OF ABOVE CALCULATIONS	\$1,522.00
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY				\$0.00
<input type="checkbox"/> FILING IN NON-ENGLISH LANGUAGE			+ \$130 =	\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT			+ \$40 =	\$0.00
			TOTAL	\$1,522.00

Please charge Deposit Account No. 15-0030 in the amount of A duplicate copy of this sheet is enclosed.

A check in the amount of **\$1,522.00** to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBOLON, SPIVAK, McCLELLAND,
MAHER & NEUSTADT, P.C.Norman F. Oblon
Registration No. 24,618Daniel J. Pereira, Ph.D.
Registration No. 45,513Date: 02/06/01**22850**Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/00)